Background: The development of thromboembolism is one of the most common complications of neuroendovascular procedures. Although several small studies have deemed clopidogrel safe and effective in the prevention of intracranial stent thrombosis, ticagrelor has yet to be assessed in this setting. Objective: The objective of this study was to retrospectively evaluate the safety and efficacy of ticagrelor in patients undergoing neuroendovascular procedures. Methods: A retrospective review of patients receiving ticagrelor following neuroendovascular aneurysm repair. Results: A total of 5 patients undergoing neuroendovascular aneurysm repair received ticagrelor for a median of 5 days while hospitalized. Three patients were treated with stent-assisted coiling, while 2 received pipeline embolization devices. All patients received additional low-dose aspirin therapy. One patient received ticagrelor after experiencing a thrombotic event on clopidogrel, while a second patient was treated with ticagrelor after developing a dermatologic reaction to clopidogrel. Three (60%) patients were successfully treated and discharged on ticagrelor therapy. Two patients experienced cerebrovascular accidents following aneurysm repair while receiving ticagrelor, one of which was potentially due to medication omission. One (20%) patient receiving ticagrelor experienced a small retroperitoneal hematoma; however, ticagrelor therapy was continued without further complication. Conclusion: Therapy with ticagrelor may be a safe and effective treatment option for patients undergoing neuroendovascular aneurysm repair. However, future studies are warranted to substantiate these findings.
Introduction
The development of thromboembolism is one of the most common complications of neuroendovascular procedures such as aneurysm coiling and intracranial stent placement. 1 These procedures can lead to intimal injury of the arterial vessel and release of procoagulant tissue factors, resulting in the formation of a platelet-rich thrombus. 2 Thromboembolism can occur as the result of thrombus formation on catheters and devices (stents, coils) or from intimal injury to the arterial vessel from the equipment used to perform these procedures. 3 Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, such as clopidogrel, has become the main stay of acute coronary syndrome management, as it has been shown to reduce thromboembolic complications following angioplasty and stent placement. 4, 5 As the devices used in most neuroendovascular procedures are similar to those used in coronary interventions, the use of dual antiplatelet therapy has become a standard practice following such procedures. In fact, one consensus conference on intracranial atherosclerotic disease utilized trial results from coronary intervention literature to support the recommendation for the use of dual antiplatelet therapy. 6 Furthermore, small studies have demonstrated that dual antiplatelet therapy with aspirin and clopidogrel is safe and effective in patients undergoing neuroendovascular procedures. 2, 7 While most patients tolerate antiplatelet therapy with clopidogrel, there are patients who experience stent thrombosis and intolerance. Inadequate responses to clopidogrel resulting in thrombosis have become a growing concern among neurointerventionalists. As clopidogrel is a prodrug, it requires activation via the cytochrome P450 system to adequately inhibit adenosine diphosphate receptor activation. 8 Because of genetic polymorphisms, the activation of clopidogrel can vary significantly between individual patients. These polymorphisms can lead to significant reductions in platelet inhibition and therefore increase the risk of thromboembolic complications. 9 Currently, genetic tests to identify polymorphisms are available and cost a few hundred dollars-often covered to some degree by health insurance. Efforts to intensify clopidogrel dosing to achieve adequate platelet inhibition have not proven beneficial. In one study by Nordeen and colleagues, dose intensification in clopidogrel nonresponders did not have a significant effect on thrombotic or hemorrhagic events. However, resistant patients who experienced complications demonstrated a higher rate of mortality at 30 and 90 days. 10 Since the Food and Drug Administration's (FDA) approval of clopidogrel, two additional thienopyridine derivatives have been approved for similar indications-prasugrel and ticagrelor. Unlike clopidogrel, these agents do not require activation via the cytochrome P450 system and thus have a reduced risk of suboptimal platelet inhibition. Additionally, both of these agents are more potent platelet aggregation inhibitors and have been shown in cardiovascular trials to be superior to clopidogrel in reducing stent thrombosis. 11, 12 The greater potency of platelet inhibition and the lower risk of inadequate response have led to the use of these agents in patients undergoing neuroendovascular repair. Although a novel practice, there are several published reports demonstrating the efficacy and safety of prasugrel in aneurysm coiling and stent-assisted coiling. These reports suggest that in clopidogrel nonresponders, prasugrel may be an effective option. However, due to its more potent platelet inhibition, prasugrel is also associated with a higher risk of bleeding. [13] [14] [15] [16] Ticagrelor is a newer P2Y12 inhibitor that is approved for use in patients with acute coronary syndromes undergoing percutaneous stent placement. Although data exist using the P2Y12 inhibitor clopidogrel in patients undergoing neuroendovascular coiling and stent placement, currently, only 1 study has evaluated the use of ticagrelor in this patient population. Hanel and colleagues evaluated the use of ticagrelor in 18 patients undergoing neuroendovascular procedures who were determined to be clopidogrel nonresponders. None of the study subjects experienced a thrombotic or hemorrhagic event, and the authors concluded that ticagrelor may be a suitable alternative to clopidogrel. 17 Although this study provides promising preliminary data, more evidence is needed before ticagrelor can be accepted as a first-line option. The objective of this study was to retrospectively evaluate the use of ticagrelor in patients undergoing neuroendovascular procedures.
Methods
Prior to performing the study, the institutional review board at the University of Miami (Miami, Florida) reviewed and approved the study protocol. Electronic medical records were retrospectively reviewed for all patients who received ticagrelor and underwent neuroendovascular procedure at Jackson Memorial Hospital from October 1, 2012, through September 30, 2014. Patients were followed from admission to discharge. Data collection included patient demographics, thromboembolic events, and hemorrhagic complications.
Results

Case 1
A 58-year-old Hispanic female with a medical history of hypertension was admitted for management of several unruptured intracranial aneurysms. Two days prior to angiography, the patient received a 180 mg loading dose of ticagrelor followed by 90 mg twice daily in addition to aspirin 81 mg daily. The patient was then treated with a pipeline embolization device to the right internal carotid artery (ICA) without complication. That evening, after the patient expressed stroke-like symptoms, a magnetic resonance imaging (MRI) was performed, which revealed multiple cortical shower emboli in the right middle cerebral artery (MCA) area. Due to a concern for ticagrelor resistance, the agent was discontinued and the patient was started on a heparin infusion at a dose of 12 U/kg/h titrated to an activated partial thromboplastin time of 50 to 70 seconds. The following day, clopidogrel 75 mg daily was initiated and the aspirin was increased to 325 mg daily. Heparin was continued for a total of 5 days. The patient experienced no further thrombotic complications on this antiplatelet regimen while hospitalized. It was subsequently discovered that on the day of the procedure, the patient's morning ticagrelor dose was delayed by 6 hours and the evening dose was not administered as the patient was vomiting. While receiving ticagrelor, the patient did not receive any medications that could have interacted with ticagrelor and also did not receive any therapy associated with an increased thromboembolic risk.
Case 2
A 66-year-old Caucasian female with a medical history of hypertension, hyperlipidemia, breast cancer, and migraine was transferred from an outside hospital for the treatment of an unruptured basilar tip aneurysm. While at the outside hospital, the patient was determined to be a clopidogrel nonresponder based on platelet function studies; however, these results could not be confirmed. The patient was loaded with 1 dose of ticagrelor 180 mg followed by 90 mg twice daily and aspirin 325 mg followed by 81 mg daily. Three days following the initiation of dual antiplatelet therapy, the patient underwent angiography with the intent to perform stent-assisted coiling of the aneurysm. However, coil embolization failed due to extracranial vertebral artery dissection during stent deployment. Subsequently, a Neuroform (Boston Scientific Target, Fremont, California) stent was placed in the right posterior cerebral artery (PCA) to the mid-basilar artery and the decision was made to stage the procedure. The day following the procedure, the patient's hemoglobin decreased from 12.0 to 7.1 g/dL, and a small retroperitoneal hematoma was identified. The next day, the patient's hemoglobin recovered to 8.8 g/dL without intervention. The patient was discharged on ticagrelor 90 mg twice daily and aspirin 81 mg daily. Within the next 2 months, the patient underwent successful stenting of the left PCA to the upper basilar artery with an Enterprise stent (Codman Neurovascular, Raynham, Massachusetts) and embolization of the basilar tip aneurysm while receiving aspirin and ticagrelor without thrombotic or hemorrhagic complication. It should be noted that during the time of hematoma, the patient was also receiving thromboprophylaxis with enoxaparin 40 mg subcutaneously once daily. Such therapy may enhance the effect of antiplatelet therapy.
Case 3
A 63-year-old Hispanic female with a medical history of hypertension and diabetes was admitted following a diagnostic angiogram that revealed a right posterior communicating artery aneurysm that warranted flow diversion with a pipeline embolization device. Deployment of the pipeline embolization device was uneventful; however, the procedure took several hours and a follow-up angiogram was required to successfully open the stent and restore circulation. Prior to the procedure, the patient was loaded with 300 mg of clopidogrel followed by 75 mg daily, in addition to 325 mg of aspirin followed by 81 mg daily. The next day, the patient demonstrated left-sided hemiplegia, and MRI showed a small capsular infarct on the right posterior limb of the internal capsule. Platelet function studies including collagen-epinephrine closing time and collagenadenosine diphosphate closing time were performed; neither of which was prolonged. The patient was therefore deemed a nonresponder to clopidogrel. The patient was then given a loading dose of ticagrelor 180 mg followed by 90 mg twice daily. Seven days following device placement, follow-up angiography showed negative results. However, shortly after angiography, the patient became less responsive and experienced left arm weakness. An MRI showed occlusion of the right ICA. A second angiography revealed complete stent thrombosis, and partial recanalization of the stent was achieved; the frontal branch of the right MCA remained persistently occluded. After several days in the intensive care unit and a complicated hospital course, the patient was discharged on aspirin 81 mg daily and experienced no further complications while hospitalized. Upon investigation, the patient did not receive any concomitant medications that may alter the efficacy of ticagrelor.
Case 4
A 36-year-old Caucasian male with a medical history of hypertension was admitted for basilar trunk aneurysm repair. Prior to endovascular treatment, the patient developed a maculopapular rash while receiving antiplatelet therapy with clopidogrel. Clopidogrel was subsequently discontinued, and the patient was started on ticagrelor 180 mg followed by 90 mg twice daily in addition to aspirin 81 mg daily. That same day following initiation of ticagrelor, the patient underwent successful stentassisted coiling of his aneurysm with a Neuroform EZ stent (Boston Scientific). The patient experienced no complications while in the hospital and was prescribed ticagrelor 90 mg twice daily and aspirin 81 mg once daily upon discharge.
Case 5
A 61-year-old African American female with a medical history of hypertension and myocardial infarction requiring placement of 2 stents was electively admitted for endovascular management of a basilar tip aneurysm. Prior to admission, the patient was receiving ticagrelor 90 mg twice daily and aspirin 81 mg daily for the management of her coronary artery disease, which was continued upon admission. The patient underwent stentassisted coiling without complication with a Neuroform EZ (Boston Scientific stent. The patient's hospital stay was uneventful and she was discharged with ticagrelor 90 mg twice daily and aspirin 81 mg once daily.
Discussion
Thromboembolic complications arising from neuroendovascular treatment of cerebral aneurysms are associated with significant morbidity. 18 In an effort to prevent these events, antiplatelet therapy is often administered. This practice stems from a trial that evaluated the use of intravenous acetylsalicylic acid during coil embolization with the Guglielmi detachable coil (Stryker Neurovascular, Fremont, California). Patients were randomized to 250 mg of intravenous acetylsalicylic acid administered during coiling after deployment of the first coil and/or placebo. Treatment with acetylsalicylic acid significantly reduced the rate of thromboembolic events (8.8% vs 17.6%; P ¼ .028). 19 Results of this trial sparked further utilization of antiplatelet therapy with aspirin in this patient population.
Shortly following this study, the FDA approved the thienopyridine derivative clopidogrel for use in patients with acute coronary syndromes. In combination with aspirin, clopidogrel was shown to reduce the composite outcome of cardiovascular death, myocardial infarction, or urgent target vessel revascularization in patients with non-ST-segment elevated myocardial infarction undergoing percutaneous coronary intervention. 20 Given the similarities in procedures and risk of thrombosis, the use of clopidogrel with and without aspirin expanded to neuroendovascular coiling and stenting. The efficacy of this practice was assessed via a retrospective cohort study which evaluated the use of both preprocedure and postprocedure antiplatelet therapy. Yamada and colleagues found that postprocedural clopidogrel with and without aspirin significantly reduced the rate of transient ischemic attack or stroke within 60 days as compared to placebo. Additionally, the use of preprocedural antiplatelet therapy was associated with a further reduction in thromboembolic complications. 21 Several studies have reiterated these results, and the use of antiplatelet therapy with clopidogrel and/or aspirin has become standard of care in these populations. 22, 23 As demonstrated by our case series, ticagrelor may be a potential alternative to clopidogrel in patients undergoing pipeline embolization or stent-assisted coiling. Four of the 5 patients were effectively loaded with 180 mg of ticagrelor and concomitant aspirin. While 2 patients did experience thrombotic events while receiving ticagrelor, these events may have been due to missed doses and underlying hypercoagulable states. Additionally, there was only 1 hemorrhagic event which resolved without any intervention. As the rate of major hemorrhagic events with clopidogrel exceeds 10% in this patient population, these results are promising. 24 Finally, we demonstrate that in a patient previously receiving ticagrelor for coronary stent placement, continuation of this therapy is effective at reducing thrombosis related to neuroendovascular procedures. Results of our study are similar to those of Hanel and colleagues, which demonstrated the efficacy and safety of ticagrelor in a similar patient population.
Although this case series is promising, there are several limitations. Being a retrospective chart review, there are several factors not taken into consideration due to this methodology. Patients were only evaluated during hospital admission, and information on thromboembolic and hemorrhagic events occurring after discharge from the hospital was unavailable. Duration of therapy with ticagrelor could not be determined. Therefore, conclusions cannot be made on the long-term safety and efficacy of ticagrelor in this patient population. Unfortunately, platelet reactivity was not measured in all patients receiving ticagrelor, and platelet reactivity could not be confirmed in the patient admitted from the outside hospital with presumed clopidogrel resistance. Therefore, the role of ticagrelor in clopidogrel nonresponders cannot be confirmed. Lastly, as a case series, the sample size is extremely small and should be interpreted with caution. As the Hanel study was also quite small, larger studies are warranted to substantiate these findings. A prospective study evaluating the use of ticagrelor and clopidogrel over several months would best evaluate the use of ticagrelor in this setting.
Conclusion
This series demonstrates that ticagrelor may be an effective alternative to clopidogrel in reducing thrombotic complications in select patients undergoing stent-assisted coiling and pipeline embolization. Hemorrhagic risk and patient compliance should be considered prior to initiation of therapy. As this sample size is quite small and only 1 other small cohort exists, further investigation is warranted to better evaluate the safety and efficacy of ticagrelor in patients undergoing neuroendovascular procedures.
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